ARS Pharmaceuticals, Inc.
SPRY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001671858
No open-market purchases or sales by ARS Pharmaceuticals, Inc. insiders were filed in the last 90 days; 208 institutions reported holding it in 13F filings for Q2 2026, worth $726.0M in total; Third Point is the only superinvestor holding it.
13F holders, Q1 2024
Institutional positions in ARS Pharmaceuticals, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 113
- +13 vs. Q4 2023
- Shares held
- 59.9M
- −5.53M (−8.5%) vs. Q4 2023
- Total value
- $612.1M
- +$253.6M (+70.7%) vs. Q4 2023
- New holders
- 27
- 36 more added
- Sold out
- 14
- 27 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SPRY on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 208 | $726.0M |
| Q1 2026 | 203 | $757.5M |
| Q4 2025 | 191 | $1.05B |
| Q3 2025 | 188 | $840.4M |
| Q2 2025 | 188 | $1.48B |
| Q1 2025 | 184 | $958.9M |
| Q4 2024 | 166 | $752.3M |
| Q3 2024 | 151 | $928.4M |
| Q2 2024 | 115 | $533.0M |
| Q1 2024 | 113 | $612.1M |
| Q4 2023 | 100 | $358.5M |
| Q3 2023 | 97 | $251.6M |
| Q2 2023 | 92 | $369.0M |
| Q1 2023 | 90 | $347.7M |
| Q4 2022 | 73 | $427.9M |
| Q3 2022 | 61 | $160.4M |
| Q2 2022 | 64 | $110.5M |
| Q1 2022 | 70 | $94.7M |
| Q4 2021 | 72 | $200.5M |
| Q3 2021 | 74 | $288.4M |
| Q2 2021 | 76 | $864.6M |
| Q1 2021 | 68 | $1.21B |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding ARS Pharmaceuticals, Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Lindbrook Capital, LLC | 700 | $7.15K | 0.00% | 00.0% | Unchanged |
| Pacer Advisors, Inc. | 516 | $5.27K | 0.00% | +516 | New |
| Daiwa Securities Group Inc. | 367 | $4.00K | 0.00% | 00.0% | Unchanged |
| Quadrant Capital Group LLC | 347 | $3.55K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 231 | $2.36K | 0.00% | −6,834−96.7% | Reduced |
| Federated Hermes, Inc. | 169 | $1.73K | 0.00% | +169 | New |
| US Bancorp | 155 | $1.58K | 0.00% | 00.0% | Unchanged |
| Comerica Bank | 140 | $1.43K | 0.00% | +140 | New |
| GAMMA Investing LLC | 100 | $1.02K | 0.00% | +24+31.6% | Added |
| Allworth Financial LP | 82 | $839 | 0.00% | +82 | New |
| C M Bidwell & Associates Ltd | 48 | $491 | 0.00% | +20+71.4% | Added |
| The PNC Financial Services Group, Inc. | 8 | $82 | 0.00% | 00.0% | Unchanged |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 5 | $51 | 0.00% | +5 | New |
| Charles Schwab Trust Co | 0 | $0 | 0.00% | −3,996,071−100.0% | Sold out |
| Baker Bros. Advisors LP | 0 | $0 | 0.00% | −2,006,451−100.0% | Sold out |
| Nantahala Capital Management, LLC | 0 | $0 | 0.00% | −1,596,504−100.0% | Sold out |
| Tang Capital Management LLC | 0 | $0 | 0.00% | −409,463−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −104,067−100.0% | Sold out |
| Denali Advisors LLC | 0 | $0 | 0.00% | −87,500−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −77,162−100.0% | Sold out |
| Tejara Capital Ltd | 0 | $0 | 0.00% | −73,739−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −68,157−100.0% | Sold out |
| ExodusPoint Capital Management, LP | 0 | $0 | 0.00% | −38,022−100.0% | Sold out |
| Brendel Financial Advisors LLC | 0 | $0 | 0.00% | −18,281−100.0% | Sold out |
| Mirae Asset Global Investments Co., Ltd. | 0 | $0 | 0.00% | −16,534−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −16,500−100.0% | Sold out |
| AJOVista, LLC | 0 | $0 | 0.00% | −7,822−100.0% | Sold out |